Table 1.
Baseline characteristics. Values are number (percentage) unless stated otherwise
| Characteristics | Rosuvastatin group (n=2204) | Atorvastatin group (n=2196) |
|---|---|---|
| Mean (SD) age (years) | 65 (10) | 65 (10) |
| Women | 602 (27.3) | 626 (28.5) |
| Mean (SD) weight (kg) | 67 (11) | 67 (10) |
| Mean (SD) height (cm) | 164 (8) | 165 (8) |
| Mean (SD) body mass index | 24.8 (3.0) | 24.7 (2.8) |
| Current smoker | 291 (13.2) | 312 (14.2) |
| Comorbidities | ||
| Hypertension | 1498 (68.0) | 1439 (65.5) |
| Diabetes mellitus | 725 (32.9) | 743 (33.8) |
| Diabetes mellitus: insulin treatment | 83 (3.8) | 79 (3.6) |
| Chronic kidney disease* | 149 (6.8) | 170 (7.7) |
| End stage kidney disease: receiving dialysis | 14 (0.6) | 15 (0.7) |
| Mean (SD) eGFR (mL/min/1.73 m2) | 88.1 (17.4) | 87.9 (17.9) |
| Medical history | ||
| Percutaneous coronary intervention | 1258 (57.1) | 1199 (54.6) |
| Coronary artery bypass grafting surgery | 167 (7.6) | 167 (7.6) |
| Stroke | 140 (6.4) | 123 (5.6) |
| Clinical presentation at randomisation: | ||
| Acute myocardial infarction <1 year | 175 (7.9) | 163 (7.4) |
| Unstable angina or revascularisation <1 year | 404 (18.3) | 384 (17.5) |
| Myocardial infarction >1 year ago | 322 (14.6) | 353 (16.1) |
| Unstable angina or revascularisation >1 year ago | 906 (41.1) | 878 (40.0) |
| Detection of asymptomatic CAD at screening | 397 (18.0) | 418 (19.0) |
| Lipid lowering treatment before randomisation | ||
| Statin intensity: | ||
| High | 533 (24.2) | 572 (26.0) |
| Moderate | 1277 (57.9) | 1247 (56.8) |
| Low | 43 (2.0) | 50 (2.3) |
| None | 351 (15.9) | 327 (14.9) |
| Ezetimibe | 259 (11.8) | 220 (10.0) |
| Mean (SD) lipids (mmol/L) | ||
| LDL cholesterol | 2.2 (0.9) | 2.3 (0.8) |
| HDL cholesterol | 1.2 (0.3) | 1.2 (0.3) |
| Total cholesterol | 4.1 (1.0) | 4.1 (0.9) |
| Triglycerides | 1.6 (0.9) | 1.6 (0.9) |
CAD=coronary artery disease; eGFR=estimated glomerular filtration rate; HDL=high density lipoprotein; LDL=low density lipoprotein; SD=standard deviation.
*
Defined as eGFR <60 mL/min/1.73 m2 of body surface area.